Activity Goals. Activity Goals Program Overview.

Slides:

Advertisements

Similar presentations

Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation 1 Phase III Randomized, Open-Label, Multicenter Trial (BRIM3) Comparing BRAF Inhibitor.

Advertisements

About these slides SPEC – Short Presentation in Emerging Concepts Provided by the CAP as an aid to pathologists to facilitate discussion on the topic.

About these slides SPEC – Short Presentation in Emerging Concepts Provided by the CAP as an aid to pathologists to facilitate discussion on the topic.

Two Year Estimate of Overall Survival in COMBI-v, a Randomized, Open-Label, Phase 3 Study Comparing the Combination of Dabrafenib and Trametinib With Vemurafenib.

Prior to the start of the program, check your syllabus to ensure you have the participant survey and CME evaluation: In the front of your syllabus Remove.

What should patients with BRAF mutant melanoma receive as front line therapy? Antoni Ribas, M.D. Professor of Medicine Professor of Surgery Professor of.

Melanoma Nati Lerman MD Division of Hematology/Medical Oncology MD Anderson Cancer Center at Cooper September 2016.

Stage III and IV Malignant Melanoma Jennifer Carter 09/12/17.

Pharmacogenomics: towards personalized medicine

Bladder Cancer: A New Era in Treatment

Combined Inhibition of PD-L1, MEK, and BRAF Active in Advanced Melanoma CCO Independent Conference Highlights of the 2015 ASCO Annual Meeting* May 29 -

Evolving Paradigms in Recurrent/Metastatic SCCHN

A New Path Forward: Immune Checkpoint Inhibitors in Bladder Cancer

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States and data.

Treatment Algorithms in Melanoma: Past, Present, and Future

The Immune System. The Immune System Adaptive Immune Response.

What to Do Next: Sequencing of Therapy in Patients With Metastatic CRC

Advanced NSCLC Without Actionable Mutations

State of the Art in HCC: Immune Checkpoint Modulation

New Patient Journeys in Non-small cell lung cancer

Discussion Outline Cells of the Immune System.

Essential Concepts in Harnessing the Immune System in Head and Neck Cancer.

Metastatic Renal Cell Carcinoma

Program Goals. Targeting New Pathways for Overcoming Endocrine Resistance in Breast Cancer.

Learning Objectives. A Multidisciplinary Approach in Advanced NSCLC in the Era of Immuno-Oncology.

Targeting Thyroid Cancer

Activity Goals. Activity Goals Discussion Topics.

BRAF inhibitor: targeted therapy in hairy cell leukemia

Program Goals Introduction Case 1: A 44-Year-Old Woman.

Immunotherapy in Pancreatic Cancer: Thinking Outside the Box

Latest Advances in Chemotherapeutic, Targeted, and Immune Approaches in the Treatment of Metastatic Melanoma Darshil J. Shah, MD, MPH, Roxana S. Dronca,

Advanced Lung Cancers: What's on the Horizon?

The Emerging Role of Immunotherapy in Hodgkin Lymphoma

Presented By Johanna Bendell at 2016 ASCO Annual Meeting

A Spotlight on PI3K Inhibition in Relapsed/Refractory B-Cell Lymphoma

Essential Concepts in the Use of Immunotherapies in Bladder Cancer

Braf-MUTATION POSITIVE melanoma: a case conference

Advancing Care in Genitourinary Cancer: Perspectives From Chicago

Hiding in Plain Sight: How Cancer Evades the Immune System

Targeted Therapies in Melanoma: Translational Research at Its Finest

How to Effectively Manage Patients With Cutaneous Squamous Cell Carcinoma.

Evolving Concepts in the Management of Head and Neck Cancers

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Immune Checkpoint Inhibitors in Lung Cancer

New Classes of Therapy in Multiple Myeloma

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Advances in Gastrointestinal Cancers

Patient-Centered Management in BRAF-Positive Metastatic Melanoma

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Changing the Paradigm of Treatment in Patients With Hodgkin Lymphoma

Progress of the NSCLC Revolution

The Changing Field of Melanoma: Ipilimumab.

Do the Side Effects of BRAF Inhibitors Mimic RASopathies?

Challenges and Opportunities

Preparing for Checkpoint Inhibitors in Breast Cancer

Adjuvant Therapy in Melanoma

The RAF Inhibitor Paradox Revisited

From Adjuvant to Metastatic in Melanoma

Immune Checkpoint Inhibitors in EGFR-Mutated NSCLC

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States, and data.

Activity Goals. Clinical Considerations in the Use of Immune Checkpoint Inhibitors in Advanced NSCLC.

T55delinsRT mutation in MEK1 is responsible for resistance to vemurafenib in M032R4 Somatic mutations present in each of these metastases, revealing that.

Model of the BET and MEK inhibitor combination therapy to treat melanoma with NRAS mutation and immune therapy resistance Model of the BET and MEK inhibitor.

Signaling induced by BRAF L597R and L597S is sensitive to BRAF and MEK inhibitors. Signaling induced by BRAF L597R and L597S is sensitive to BRAF and MEK.

Clinical Considerations in the Use of Checkpoint Inhibitors Breast Cancer.

Going Beyond EXTREME in Head and Neck Cancer

Moving Care Forward in Advanced Gastric Cancer

Current Status of Biomarkers for Immune Checkpoint Inhibitors

Targeting Glioblastoma: EGFR and Novel Approaches to Therapy

Presentation transcript:

Activity Goals

Program Overview

Final Results: Trial of Vemurafenib + Cobimetinib vs Vemurafenib

Phase 3: Dabrafenib and Trametinib (COMBI-d) Study

Baseline Activities of Cell Signaling Pathways on Combined BRAF and MEK Inhibition

Results From the Combination of BRAF/MEK With PD-L1 Inhibitors

Selumetinib vs Temozolomide for Uveal Melanoma

Mutations in Uveal Melanoma

PRAME Expression: Response to Immunotherapy

Comparison Between Uveal Melanomas and Cutaneous Melanoma

Mutations in Melanoma

MAP-Kinase Pathway and MITF Levels

Proinflammatory Signals Contribute to Escape From T-cell Attack

MASTERKEY-265: A Phase 1b/3 Study of T-VEC + Pembrolizumab (NCT02263508)

Preliminary Efficacy -- Best Overall Response (Unconfirmed)

Phase I/2 Study of Epacadostat in Combination With Pembrolizumab

Conclusions

Two Signals for T-Cell Activation

PD-1/PD-L1

PD-L1 Expression

Response Rates: Immunotherapy for Melanoma

Pembrolizumab + Low-Dose Ipilimumab

Pooled Analysis of Mucosal Melanoma

Abbreviations

Abbreviations (cont)

Abbreviations (cont)

Abbreviations (cont)